🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease

Recruitingn/aAges 40 Years - 85 YearsAllCentre Hospitalier Universitaire, Amiens
NCT05785156 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Dege

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients between 40 and 85 years old, * French native language, * Social Security affiliation. * University Memory Clinic for: Mild severity disorder (MMSE\> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011 * to MCL according to McKeith criteria * to FTLD according to Rascovsky 2011 criteria * BBD according to Armstrong's criteria * related to PSP according to Höglinger criteria Exclusion Criteria: * Mental retardation or guardianship * Previously diagnosed dementia * Other current or past brain condition * severe head trauma * epilepsy prior to stroke still requiring previous treatment * Parkinson disease, multiple sclerosis... * brain tumor or brain radiation therapy * Current or past schizophrenia or psychosis * Active or past psychiatric disorders requiring a stay\> 2 days in a specialized environment * Contra indication to MRI * Comorbidity with life expectancy \<1 year * Comorbidity affecting cognition in particular: * Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome * opiate or cocaine addiction or opiate withdrawal syndrome * renal failure (dialysis or creatinine clearance \<30) * hepatic failure (spontaneous INR\> 1.5 or PT \<60%) * respiratory failure requiring oxygen therapy * heart failure (orthopnea\> 2 pillows) * persistent vigilance disturbances (NIHSS1a score ≤1) * cancer with paraneoplastic syndrome * treatment with gold salts, D Penicillamine or other treatment with cognitive effect * Patient under guardianship or curators or private under public law * Pregnant and / or lactating wom
💊

What it tests

  • quick tests
📍

Where

1 site
CHU Amiens
Amiens, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy